Tags

Type your tag names separated by a space and hit enter

Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease.
Neurosci Lett. 2008 Dec 19; 448(1):143-7.NL

Abstract

The acetylcholinesterase inhibitor (AChEI) galantamine is currently used to treat mild to moderate Alzheimer's disease (AD), and it has been suggested to have several neuroprotective effects. To investigate the potential application of this drug to the treatment of Huntington's disease, we examined whether galantamine can reduce the striatal degeneration induced by the mitochondrial toxin, 3-nitropropionic acid (3NP). 3NP (63 mg/kg/day) was delivered to Lewis rats by osmotic pumps for 5 consecutive days, and the rats received intraperitoneal administration of either different concentrations of galantamine (1mg/kg/day or 10 mg/kg/day, twice daily) or vehicle (saline) throughout the experiment. Galantamine attenuated the 3NP-induced neurologic deficits on days 2-5. Galantamine-treated rats showed smaller striatal lesion volumes measured by Nissl staining and lower numbers of TUNEL(+) apoptotic cells when compared to the vehicle-treated rats. Galantamine failed to reduce the striatal lesion volume when co-administered with mecamylamine, a nicotinic acetylcholine receptor antagonist. Our data indicate that galantamine can attenuate neurodegeneration in a Huntington's disease model by modulating nAChR.

Authors+Show Affiliations

Neurodegeneration Research Laboratory, Department of Neurology, Clinical Research Institute, Seoul National University Hospital, Seoul, South Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18938211

Citation

Park, Jung-Eun, et al. "Galantamine Reduces Striatal Degeneration in 3-nitropropionic Acid Model of Huntington's Disease." Neuroscience Letters, vol. 448, no. 1, 2008, pp. 143-7.
Park JE, Lee ST, Im WS, et al. Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease. Neurosci Lett. 2008;448(1):143-7.
Park, J. E., Lee, S. T., Im, W. S., Chu, K., & Kim, M. (2008). Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease. Neuroscience Letters, 448(1), 143-7. https://doi.org/10.1016/j.neulet.2008.10.020
Park JE, et al. Galantamine Reduces Striatal Degeneration in 3-nitropropionic Acid Model of Huntington's Disease. Neurosci Lett. 2008 Dec 19;448(1):143-7. PubMed PMID: 18938211.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Galantamine reduces striatal degeneration in 3-nitropropionic acid model of Huntington's disease. AU - Park,Jung-Eun, AU - Lee,Soon-Tae, AU - Im,Woo-Seok, AU - Chu,Kon, AU - Kim,Manho, Y1 - 2008/10/14/ PY - 2008/09/17/received PY - 2008/10/01/accepted PY - 2008/10/22/pubmed PY - 2009/4/17/medline PY - 2008/10/22/entrez SP - 143 EP - 7 JF - Neuroscience letters JO - Neurosci Lett VL - 448 IS - 1 N2 - The acetylcholinesterase inhibitor (AChEI) galantamine is currently used to treat mild to moderate Alzheimer's disease (AD), and it has been suggested to have several neuroprotective effects. To investigate the potential application of this drug to the treatment of Huntington's disease, we examined whether galantamine can reduce the striatal degeneration induced by the mitochondrial toxin, 3-nitropropionic acid (3NP). 3NP (63 mg/kg/day) was delivered to Lewis rats by osmotic pumps for 5 consecutive days, and the rats received intraperitoneal administration of either different concentrations of galantamine (1mg/kg/day or 10 mg/kg/day, twice daily) or vehicle (saline) throughout the experiment. Galantamine attenuated the 3NP-induced neurologic deficits on days 2-5. Galantamine-treated rats showed smaller striatal lesion volumes measured by Nissl staining and lower numbers of TUNEL(+) apoptotic cells when compared to the vehicle-treated rats. Galantamine failed to reduce the striatal lesion volume when co-administered with mecamylamine, a nicotinic acetylcholine receptor antagonist. Our data indicate that galantamine can attenuate neurodegeneration in a Huntington's disease model by modulating nAChR. SN - 0304-3940 UR - https://www.unboundmedicine.com/medline/citation/18938211/Galantamine_reduces_striatal_degeneration_in_3_nitropropionic_acid_model_of_Huntington's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0304-3940(08)01390-6 DB - PRIME DP - Unbound Medicine ER -